HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Summary Full Text Full Text (PDF) Supplemental Data All Versions of this Article: fj.05-5299fjev1 20/8/1197    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamada, M. Articles by Matsuzaki, M. Search for Related Content PubMed PubMed Citation Articles by Yamada, M. Articles by Matsuzaki, M.

Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy

Michio Yamada^*,, Yasuhiro Ikeda^*,,1, Masafumi Yano, Koichi Yoshimura^*, Shizuka Nishino^*, Hidekazu Aoyama^*,, Lili Wang, Hiroki Aoki^* and Masunori Matsuzaki^*,

^* Department of Molecular Cardiovascular Biology Yamaguchi University School of Medicine;

Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, Ube, Japan; and

Medical Genetics Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

¹Correspondence: Department of Molecular Cardiovascular Biology, Yamaguchi University School of Medicine, 1–1-1 Minami-Kogushi, Ube 755-8505, Japan. E-mail: ysikeda{at}yamaguchi-u.ac.jp

ABSTRACT

The type 1 protein phosphatase (PP1) has been reported to be overactivated in the failing heart, leading to a depression in cardiac function. We investigated whether in vivo PP1 inhibition by myocardial gene transfer of inhibitor-2 (INH-2), an endogenous PP1 inhibitor, alleviates heart failure (HF) progression in the cardiomyopathic (CM) hamster, a well-established HF model. Adenoviral INH-2 gene delivery improved % fractional shortening of the left ventricle (LV) accompanied by reduced chamber size at 1 wk. In vivo myocardial INH-2 gene delivery induced an increase in cytosolic PP1 catalytic subunit (PP1C) without inducing the corresponding increase in cytosolic PP1 activity. On the other hand, INH-2 delivery induced a decrease in microsomal PP1C, resulting in a preferential decrease in microsomal PP1 activity, thereby increasing in phospholamban phosphorylation at Ser16. INH-2 gene transfer alleviated brain natriuretic peptide expression, presumably reflecting improved cardiac function. Moreover, adeno-associated virus-mediated INH-2 gene delivery significantly extended the survival time for 3 mo. These results indicate that increased PP1 activity is an exacerbating factor during progression of genetic cardiomyopathy and modulation of PP1 activity by INH-2 provides a potential new treatment for HF without activating protein kinase A signaling in cardiomyocytes.— Yamada, M., Ikeda, Y., Yano, M., Yoshimura, K., Nishino, S., Aoyama, H., Wang, L., Aoki, H., and Matsuzaki, M. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy.

This article has been cited by other articles:

				H. Chiba, N. S. Schneider, S. Matsuoka, and A. Noma A Simulation Study on the Activation of Cardiac CaMKII {delta}-Isoform and Its Regulation by Phosphatases Biophys. J., September 1, 2008; 95(5): 2139 - 2149. [Abstract] [Full Text] [PDF]

				A. El-Armouche, K. Wittkopper, F. Degenhardt, F. Weinberger, M. Didie, I. Melnychenko, M. Grimm, M. Peeck, W. H. Zimmermann, B. Unsold, et al. Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy Cardiovasc Res, August 24, 2008; (2008) cvn208v2. [Abstract] [Full Text] [PDF]

				S. Grote-Wessels, H. A. Baba, P. Boknik, A. El-Armouche, L. Fabritz, H.-J. Gillmann, D. Kucerova, M. Matus, F. U. Muller, J. Neumann, et al. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload Cardiovasc Res, August 1, 2008; 79(3): 464 - 471. [Abstract] [Full Text] [PDF]

				L. E. Vinge, P. W. Raake, and W. J. Koch Gene Therapy in Heart Failure Circ. Res., June 20, 2008; 102(12): 1458 - 1470. [Abstract] [Full Text] [PDF]

				Y. Ikeda, M. Hoshijima, and K. R. Chien Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure Physiology, February 1, 2008; 23(1): 6 - 16. [Abstract] [Full Text] [PDF]

				N. P. L. Rolim, A. Medeiros, K. T. Rosa, K. C. Mattos, M. C. Irigoyen, E. M. Krieger, J. E. Krieger, C. E. Negrao, and P. C. Brum Exercise training improves the net balance of cardiac Ca2+ handling protein expression in heart failure Physiol Genomics, May 11, 2007; 29(3): 246 - 252. [Abstract] [Full Text] [PDF]